Lung Cancer News and Research

Latest Lung Cancer News and Research

Experts share latest buzz on allergies to alcohol and tobacco

While the health benefits of drinking wine in moderation continue to make news, for some with allergies even a glass a day may be difficult to swallow. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists share the latest buzz on allergies to alcohol and tobacco.

7 Nov 2011

Sleeping Beauty transposon system plays a vital role in investigating colorectal cancer pathway

A jumping gene with the fairy tale name "Sleeping Beauty" has helped to unlock vital clues for researchers investigating the genetics of colorectal cancer.

7 Nov 2011

International research explains why measles virus spreads so quickly

An international collaboration involving Inserm has revealed how the measles virus leaves the body of an infected person to contaminate another individual. The researchers have identified a key receptor, located in the trachea, which allows the virus to spread through the air rapidly from one organism to another. The receptor, nectine-4, is also known to be a biomarker for some cancers.

5 Nov 2011

Vanderbilt-Ingram Cancer Center, LUNGevity Foundation host first Nashville Breathe Hope event

LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.

5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

Cancer responsible for 40% of all premature deaths

Cancer is responsible for killing 40 per cent of all the men and women who die prematurely between the ages of 25 and 74 in the UK - according to a new analysis of the figures released today by Cancer Research UK.

3 Nov 2011

Biomoda submits new U.S. Patent application for CyPath lung cancer assay

Cancer diagnostics company Biomoda, Inc. filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath diagnostic assay for lung cancer.

3 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

Solid organ transplant may increase risk of cancer

Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

New computer-based tool enables early diagnosis of cancer

A computer-based tool could help GPs to speed up the diagnosis and treatment of patients suffering from two of the most common forms of cancer, potentially saving thousands of lives every year.

31 Oct 2011

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

31 Oct 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

The West Clinic to partner with Methodist for cancer care

Methodist Healthcare and The West Clinic have entered into a partnership, effective January 1, 2012, to transform cancer care in the Mid-South area. The West Clinic, the region's premier cancer practice and a nationally-recognized leader in cancer research, is joining forces with Methodist to create a comprehensive, fully integrated cancer service for the benefit of Mid-South residents.

29 Oct 2011

LCA hails NCCN for lung cancer screening guidelines

Today Lung Cancer Alliance (LCA) hailed the leadership of the National Comprehensive Cancer Network (NCCN) for being the first professional society to recommend low-dose CT screening for high risk individuals and to develop comprehensive clinical practice guidelines on lung cancer screening.

29 Oct 2011